课题基金 / 基金详情

The Risk of Novel AKT Inhibition on Lethal Neuroendocrine Prostate Cancer Development

The Risk of Novel AKT Inhibition on Lethal Neuroendocrine Prostate Cancer Development
新型 AKT 抑制对致死性神经内分泌前列腺癌发展的风险
批准号：
350042
负责人：
Chen RuiQi
金额：
$1.27万
依托单位：
University of British Columbia
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2015
资助国家：
加拿大
项目状态：
已结题
起止时间：
2015-12-01 至 2016-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=350042&lang=en
关键词：
Castration Resistance Cellular Biology Cellular Differentiation Neuroendocrinology Novel Therapeutic Target Prostate Cancer Signaling Pathways Therapeutic Effects Tumors Ubiquitylation

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
One in every eight men is diagnosed with prostate cancer (PCa), rending this disease the most common cancer affecting Canadian men's health. The primary treatment for locally advanced, recurrent, or metastatic PCa is androgen receptor (AR) pathway inhibit
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金